The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial

<p>Abstract</p> <p>Background</p> <p>The aim of this study was to assess efficacy and safety of saxagliptin monotherapy for up to 76 weeks in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control, with main efficacy assessment at 24 weeks.</p&...

Full description

Bibliographic Details
Main Authors: Frederich Robert, McNeill Robert, Berglind Niklas, Fleming Douglas, Chen Roland
Format: Article
Language:English
Published: BMC 2012-07-01
Series:Diabetology & Metabolic Syndrome
Subjects:
DPP-4 inhibitor
Monotherapy
Saxagliptin
Titration
Type 2 diabetes mellitus
Online Access:http://www.dmsjournal.com/content/4/1/36

Similar Items

Similar Items